These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6296836)

  • 1. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.
    North JR; Morgan AJ; Thompson JL; Epstein MA
    Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7504-8. PubMed ID: 6296836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins.
    Morgan AJ; Epstein MA; North JR
    J Med Virol; 1984; 13(3):281-92. PubMed ID: 6327902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
    Thorley-Lawson DA; Poodry CA
    J Virol; 1982 Aug; 43(2):730-6. PubMed ID: 6287039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.
    Thorley-Lawson DA; Geilinger K
    Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5307-11. PubMed ID: 6254073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
    Hoffman GJ; Lazarowitz SG; Hayward SD
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2979-83. PubMed ID: 6248876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an Epstein-Barr virus glycoprotein which is antigenically homologous to the varicella-zoster virus glycoprotein II and the herpes simplex virus glycoprotein B.
    Emini EA; Luka J; Armstrong ME; Keller PM; Ellis RW; Pearson GR
    Virology; 1987 Apr; 157(2):552-5. PubMed ID: 3029988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells.
    Wells A; Koide N; Klein G
    J Virol; 1982 Jan; 41(1):286-97. PubMed ID: 6283120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.
    Qualtiere LF; Chase R; Vroman B; Pearson GR
    Proc Natl Acad Sci U S A; 1982 Jan; 79(2):616-20. PubMed ID: 6176998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against Epstein-Barr virus: current progress and future strategies.
    Epstein MA
    Lancet; 1986 Jun; 1(8495):1425-7. PubMed ID: 2872525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220.
    Qualtiere LF; Decoteau JF; Hassan Nasr-el-Din M
    J Gen Virol; 1987 Feb; 68 ( Pt 2)():535-43. PubMed ID: 2434608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.
    Strnad BC; Schuster T; Klein R; Hopkins RF; Witmer T; Neubauer RH; Rabin H
    J Virol; 1982 Jan; 41(1):258-64. PubMed ID: 6177865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
    Finerty S; Tarlton J; Mackett M; Conway M; Arrand JR; Watkins PE; Morgan AJ
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological properties of Junin virus proteins. I. Identification of the immunogenic glycoprotein.
    Cresta B; Padula P; de Martinez Segovia M
    Intervirology; 1980; 13(5):284-8. PubMed ID: 6250990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr (EB) virus antibodies in rheumatoid arthritis.
    Ferrell PB; Tan EM
    Springer Semin Immunopathol; 1981; 4(2):181-91. PubMed ID: 6275562
    [No Abstract]   [Full Text] [Related]  

  • 15. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
    Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
    J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides.
    North JR; Morgan AJ; Epstein MA
    Int J Cancer; 1980 Aug; 26(2):231-40. PubMed ID: 6162806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
    Gerber P; Ablashi D; Magrath I; Armstrong G; Andersen P; Trach L
    J Natl Cancer Inst; 1982 Sep; 69(3):585-90. PubMed ID: 6287082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography.
    David EM; Morgan AJ
    J Immunol Methods; 1988 Apr; 108(1-2):231-6. PubMed ID: 2832478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
    Ulaeto D; Wallace L; Morgan A; Morein B; Rickinson AB
    Eur J Immunol; 1988 Nov; 18(11):1689-97. PubMed ID: 2904885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.
    Epstein MA; Randle BJ; Finerty S; Kirkwood JK
    Clin Exp Immunol; 1986 Mar; 63(3):485-90. PubMed ID: 3011324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.